Brief: Elicio Therapeutics Says Positive Interim Data From Phase 1 Study Of Investigational Therapeutic Cancer Immunotherapy, ELI-002, In Patients With High Relapse Risk Pancreatic And Colorectal Cancer

Elicio Therapeutics

03/06/2023 14:15

June 3 (Reuters) - Angion Biomedica Corp  ELTX.O :
    * ELICIO THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM
THE
PHASE 1 STUDY OF AN INVESTIGATIONAL THERAPEUTIC CANCER
IMMUNOTHERAPY, ELI-002, IN PATIENTS WITH HIGH RELAPSE RISK
PANCREATIC AND COLORECTAL CANCER AT THE ASCO ANNUAL MEETING
    * ANGION BIOMEDICA CORP SAYS ROBUST MKRAS-SPECIFIC T CELL
RESPONSES INDUCED IN 87% OF PATIENTS
    * ANGION BIOMEDICA CORP SAYS ELI-002 WAS SHOWN TO BE
WELL-TOLERATED WITH NO DOSE LIMITING TOXICITY OR CYTOKINE
RELEASE SYNDROME
    * ANGION BIOMEDICA CORP SAYS A HIGH PROPORTION OF PATIENTS
HAD
TUMOR BIOMARKER REDUCTION (77%) WITH 32% HAVING COMPLETE
CLEARANCE

Source text for Eikon:  ID:nGNX57ZpM3 
Further company coverage:  ELTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))